PharmaMar has initiated a Phase I clinical trial of PM060184 for patients with solid tumours.

PM060184, which is a marine-derived, synthetically-produced compound, has demonstrated strong in vitro and in vivo anti-tumour activity and a favourable safety profile in preclinical toxicology studies.

The trials will be conducted in the US, France and Spain.

The primary endpoints of the trial will be to identify the drug’s dose-limiting toxicity, maximum tolerated dose and recommended dose.

The drug’s pharmacokinetic profile will also be defined and a preliminary evaluation of its anti-tumour activity in patients performed.